4basebio PLC Stock price

Equities

4BB

GB00BMCLYF79

Biotechnology & Medical Research

Delayed London S.E. 12:35:28 2024-03-28 pm EDT 5-day change 1st Jan Change
960 GBX +1.05% Intraday chart for 4basebio PLC -1.54% +41.18%
Sales 2023 * 500K 631K Sales 2024 * 2M 2.52M Capitalization 123M 155M
Net income 2023 * -7M -8.84M Net income 2024 * -7M -8.84M EV / Sales 2023 * 231 x
Net cash position 2023 * 7.2M 9.09M Net cash position 2024 * 15.1M 19.06M EV / Sales 2024 * 53.9 x
P/E ratio 2023 *
-16 x
P/E ratio 2024 *
-16 x
Employees 78
Yield 2023 *
-
Yield 2024 *
-
Free-Float 15.02%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.05%
1 week-1.54%
Current month+17.79%
1 month+21.52%
3 months+41.18%
6 months+72.20%
Current year+41.18%
More quotes
1 week
931.00
Extreme 931
980.00
1 month
820.00
Extreme 820
1 020.00
Current year
640.00
Extreme 640
1 020.00
1 year
492.00
Extreme 492
1 020.00
3 years
305.00
Extreme 305
1 020.00
5 years
175.00
Extreme 175
1 020.00
10 years
175.00
Extreme 175
1 020.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-12-21
Director of Finance/CFO 56 20-12-21
Members of the board TitleAgeSince
Director/Board Member 64 -
Director of Finance/CFO 56 20-12-21
Director/Board Member 53 -
More insiders
Date Price Change Volume
24-03-28 960 +1.05% 6,794
24-03-27 950 0.00% 1,891
24-03-26 950 -1.04% 835
24-03-25 960 -1.54% 4,419
24-03-22 975 0.00% 2,922

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock 4basebio PLC - London S.E.